Phase II randomized trial of afatinib with or without cetuximab as first-line treatment for EGFR mutated non-small cell lung cancer (NSCLC) patients (IFCT-1503 ACE-Lung)

  • Etude concernée: IFCT-1503
  • Auteurs / Authors: Cortot A B, Madroszyk A, Giroux Leprieur E, Molinier O, Quoix E, Berard H, Otto J, Rault I, Raimbourg J, Hureaux J, Moreau L, Debieuvre D, Morel H, Denis M, Amour E, Morin F, Moro-Sibilot D, Cadranel J
  • Journal / Conference: ASCO
  • Année / Year: 2019
  • PMID: Poster